Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdoid Tumor 1Osteosarcoma Recurrent 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Melanoma 1Lymphoma, Follicular 1Lung Neoplasms 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 2tazemetostat 1talazoparib 1irinotecan sucrosofate 1etoposide phosphate 1dinutuximab 1atezolizumab 1abemaciclib 1Zoledronic Acid 1X-Rays 1Tiragolumab 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Phantoms, Imaging 1Nivolumab 1Microarray Analysis 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Immunohistochemistry 1Ifosfamide 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Eflornithine 1Dasatinib 1Carboplatin 1Blotting, Western 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Rhabdoid Tumor × Eflornithine × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡